Proof
What the work has found.
Client names are removed. The numbers stay.
Pharma and medical devices.
Oncology
A 149-name KOL list, validated before a Canadian launch
59.7% of the inherited list failed inclusion criteria. We added 29 net-new specialists, including 3 National Champions the list had missed.
Neurosurgery
Precision Target Identification in Neurosurgery
We checked our approach against a benchmark list of neurosurgeons and found all 8 high-priority targets, plus 27 emerging leaders the benchmark didn’t list.
Rare disease
Precision KOL Identification for Rare Disease Market Entry
We identified the clinicians and centres that matter for a niche pediatric product in Ontario: 71 specialists ranked, 33 of them high priority.
Medical devices
10,860 physicians identified for a medical device manufacturer
A US targeting project built on public federal data, with 483 top-priority physicians confirmed by multi-year billing records.
Congresses
Four congress intelligence engagements
Real-time KOL panels, onsite interviews and abstract mapping across transplant, myeloma and hematology meetings.
Outside pharma.
Manufacturing
Four AI builds for one industrial manufacturer
264 lapsed accounts found in six years of orders, followed by sales segments, playbooks, a live dashboard and a trade show system.
Have a launch or market question that needs this level of clarity?
Start with a focused call. We can scope the question, the available signals, and what a useful output would look like for your team.